{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011854","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.215182+00:00","generated_at":"2026-06-13T08:36:20.645711+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Capricor board member Manzo resigns; appoints Paul Auwaerter, M.D. to board","bullets":["Louis Manzo resigned from board effective July 11, 2023, with no disagreement over operations.","Manzo entered a consulting agreement to perform investor relations services for Capricor.","Paul Auwaerter, M.D. appointed to board; receives initial option grant of 115,000 shares vesting over 3 years.","Auwaerter is Clinical Director at Johns Hopkins Division of Infectious Diseases with over 30 years experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011854","json":"https://secwatch.observer/filing/0001558370-23-011854.json","markdown":"https://secwatch.observer/filing/0001558370-23-011854.md","text":"https://secwatch.observer/filing/0001558370-23-011854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011854/0001558370-23-011854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011854/capr-20230711x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:36:20.645711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"480d40d995","claim":"Louis Manzo resigned as member of the Board of Directors at CAPRICOR THERAPEUTICS, INC..","evidence_excerpt":"On July 11, 2023, Mr. Louis Manzo, a member of the Board of Directors (the “Board”) of Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), resigned from the Board effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011854/0001558370-23-011854-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"4ddf9b5a82","claim":"Paul Auwaerter was elected as member of the Board of Directors at CAPRICOR THERAPEUTICS, INC..","evidence_excerpt":"On July 11, 2023, the Board elected Paul Auwaerter, M.D. as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011854/0001558370-23-011854-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}